Breast Cancer Clinical Trials in Boston

Showing 181-200 of 509 trials

FIH Study of RGT-419B Alone and With Endocrine Therapy in HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer

NCT05304962

This is a phase I, First-in-Human (FIH), open-label study to evaluate the safety, tolerability, pharmacokinetic (PK) profile, and preliminary efficacy of RGT-419B administered orally as monotherapy OR in combination with Hormonal Therapy in subjects with HR+, HER2- locally advanced and unresectable (Stage III) or metastatic (Stage IV) breast cancer whose disease has progressed during prior therapy with an approved CDK4/6i plus hormonal therapy.

Breast Cancer

Regor Pharmaceuticals Inc.64 participantsStarted Mar 2022

La Jolla, California, United States • Los Angeles, California, United States • Port Saint Lucie, Florida, United States +5 more locations

COMPLETEDPhase 2< 1 mile

A Study to Assess the Efficacy and Safety of Enzalutamide With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2 Positive (HER2+), Androgen Receptor Positive (AR+) Metastatic or Locally Advanced Breast Cancer

NCT02091960

The purpose of this study was to evaluate the efficacy of enzalutamide with trastuzumab in patients with HER2+ AR+ metastatic or locally advanced breast cancer.

HER2 AmplifiedAdvanced Breast CancerHuman Epidermal Growth Factor Receptor 2 (HER2)

Astellas Pharma Global Development, Inc.103 participantsStarted Sep 2014

Anaheim, California, United States • Los Angeles, California, United States • San Francisco, California, United States +36 more locations

FIH Study of RGT-419B Alone and With Endocrine Therapy in HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer

A Study to Assess the Efficacy and Safety of Enzalutamide With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2 Positive (HER2+), Androgen Receptor Positive (AR+) Metastatic or Locally Advanced Breast Cancer

Breast Cancer Trials in Other Cities

Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors

TeleHealth Resistance Exercise Intervention to Preserve Dose Intensity and Vitality in Elder Breast Cancer Patients

T-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCA

TAEK-VAC-HerBy Vaccine for Brachyury and HER2 Expressing Cancer

Multicenter Hologic Tomosynthesis Study

Trial of H3B-6545, in Women With Locally Advanced or Metastatic Estrogen Receptor-positive, HER2 Negative Breast Cancer

Searching for Masses and Calcifications at the Same Time in Breast Cancer Screening

Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment.

The PROMISE Study: Duavee in Women With DCIS

The OPBC-07/microNAC Study

Feasibility Study of Intraoperative Detection of Residual Cancer in Breast Cancer Patients

Contrast Enhanced Spectral Mammography vs. MRI for Breast Cancer Screening

A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer

PhII ICb With/Without Erbitux in MBC Pts

Trilaciclib in Patients Receiving Sacituzumab Govitecan-hziy for Triple Negative Breast Cancer

Trastuzumab Deruxtecan With Nivolumab in Advanced Breast and Urothelial Cancer

Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors

Tailored Axillary Surgery With or Without Axillary Lymph Node Dissection Followed by Radiotherapy in Patients With Clinically Node-positive Breast Cancer (TAXIS)

Other Conditions in Boston